Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGI-110 in Wild Type GIST, PHEO/PGL and HLRCC-Associated Kidney Cancer
NCT03165721Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Aug 2017
- Primary completion
- Feb 2020
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label trial of guadecitabine in gastrointestinal stromal tumor (GIST), pheochromocytoma, Paraganglioma (PGL) and 1 more (3 arms), sponsored by National Cancer Institute. Primary endpoint: Overall Response Rate. Started Aug 2017; status: terminated.
02
Drugs
guadecitabine
03
Conditions
gastrointestinal stromal tumor (GIST)pheochromocytomaParaganglioma (PGL)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03165721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03165721.